ʻO ka Polymorphism Gene CYP2C9 kanaka a me VKORC1

ʻO Warfarin kahi anticoagulant waha i hoʻohana pinepine ʻia i ka hana lapaʻau i kēia manawa, ʻo ia hoʻi ka mea nui i manaʻo ʻia no ka pale ʻana a me ka mālama ʻana i nā maʻi thromboembolic. Eia nō naʻe, he palena ka puka makani lapaʻau o warfarin a ʻokoʻa loa ia ma waena o nā lāhui like ʻole a me nā kānaka. Ua hōʻike ʻia e nā helu helu he ʻoi aku ka ʻokoʻa o ka mahele paʻa i nā kānaka like ʻole ma mua o 20 mau manawa. Loaʻa ke kahe koko ʻino ma 15.2% o nā maʻi e lawe ana i ka warfarin i kēlā me kēia makahiki, a he 3.5% o ia mau mea e ulu ai ke kahe koko make. Ua hōʻike ʻia e nā haʻawina Pharmacogenomic ʻo ka polymorphism genetic o ka enzyme target VKORC1 a me ka enzyme metabolic CYP2C9 o warfarin he mea nui e hoʻopilikia ana i ka ʻokoʻa o ka mahele o ka warfarin. ʻO Warfarin kahi mea hoʻopaʻa kikoʻī o ka huaora K epoxide reductase (VKORC1), a no laila e kāohi ana i ka synthesis factor clotting e pili ana i ka huaora K a hāʻawi i ka anticoagulation. Ua hōʻike ʻia he nui nā haʻawina ʻo ka polymorphism gene o ka mea hoʻolaha VKORC1 ka mea nui e hoʻopilikia ana i ka lāhui a me nā ʻokoʻa pilikino i ka mahele i koi ʻia o ka warfarin. Hoʻopili ʻia ʻo Warfarin e CYP2C9, a ʻo kāna mau mutants e lohi loa i ka metabolism o warfarin. ʻOi aku ka nui o ka pilikia o ka poʻe e hoʻohana ana i ka warfarin (ʻelua a ʻekolu manawa ke kiʻekiʻe) o ke kahe koko i ka wā mua o ka hoʻohana ʻana.